Spyre Therapeutics Reports $36.2 Million Net Loss and Increased Total Assets in Q2 2026

Spyre Therapeutics, Inc. reported its financial results for the quarter ending June 30, 2026, revealing a net loss of $36.2 million, a slight decrease from the $36.7 million loss recorded in the same period last year. The company’s total operating expenses for the quarter were $41.6 million, which included a significant gain of $40 million from the sale of in-process research and development assets. This gain was attributed to the achievement of certain milestones related to the sale of pegzilarginase to Immedica Pharma AB. Research and development expenses surged by 63% to $65.5 million, driven by increased clinical trial and manufacturing costs, as well as higher compensation expenses.

In comparison to the previous fiscal period, Spyre's financial performance showed notable changes. The company’s total assets increased to $1.17 billion as of June 30, 2026, up from $777.8 million at the end of 2025. This growth was primarily due to a rise in cash and cash equivalents, which reached $162 million, and marketable securities, which totaled $983.3 million. The accumulated deficit also widened to $1.23 billion, reflecting ongoing investments in research and development without generating revenue from product sales.

Strategically, Spyre Therapeutics has made significant advancements in its product pipeline, particularly with its investigational monoclonal antibodies targeting inflammatory bowel disease (IBD) and rheumatic diseases. The company is currently conducting the SKYLINE Phase 2 platform trial, which evaluates multiple product candidates, including SPY001, SPY002, and SPY003, in patients with moderately to severely active ulcerative colitis. Additionally, the SKYWAY Phase 2 basket trial is assessing SPY072 in various rheumatic diseases, with topline data expected in the coming months.

Operationally, Spyre has expanded its workforce, contributing to increased general and administrative expenses, which rose by 37% to $16.1 million for the quarter. The company’s cash flow from financing activities was positive, with $444.9 million raised during the first half of 2026, primarily from public offerings of common stock. As of June 30, 2026, Spyre had sufficient liquidity to fund its operations for at least one year, although it will need to secure additional financing to support ongoing research and development efforts.

Looking ahead, Spyre Therapeutics remains focused on advancing its clinical programs and expanding its product offerings. The company aims to elevate the standard of care in immunology by developing therapeutics that provide better disease control and patient convenience. However, it acknowledges the inherent risks and uncertainties in the biotechnology sector, including regulatory challenges and market conditions that could impact its future performance.